Liver Failure - Pipeline Insight, 2024

This “Liver Failure - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Liver Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Liver Failure Understanding

Liver Failure: Overview

Liver failure is the severe decline of liver function. It is an uncommon but serious condition that occurs when the liver is impaired and can no longer perform important tasks like clearing toxins from the blood or producing bile, a substance that helps digest food. Liver failure can affect infants, toddlers, older children, and adolescents. There are two kinds of liver failure: acute liver failure and chronic liver failure. Acute liver failure, also called fulminant hepatic failure, is the rapid loss of liver function over the course of days or weeks in a child who has no previous history of liver disease. Acute liver failure is a medical emergency that requires immediate medical attention. Chronic liver failure, also known as end-stage liver disease, develops over a period of months or years as the result of damage caused by long-term liver disease such as biliary atresia, metabolic liver disease, hepatitis B or hepatitis C, or cirrhosis. The most common cause of acute liver failure in children is a toxin or virus that damages the liver.

Liver Failure - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Liver Failure pipeline landscape is provided which includes the disease overview and Liver Failure treatment guidelines. The assessment part of the report embraces, in depth Liver Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liver Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Liver Failure.
• In the coming years, the Liver Failure market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Liver Failure R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Liver Failure treatment market. Several potential therapies for Liver Failure are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Liver Failure market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Liver Failure) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Liver Failure Emerging Drugs Chapters

This segment of the Liver Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Liver Failure Emerging Drugs

TAK-242: Akaza Bioscience Akaza Bioscience is a biopharmaceutical company pioneering the development of Resatorvid (TAK-242), a novel immunological therapy for the treatment of Acute-on-Chronic Liver Failure (ACLF). Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. This pan-European study aims to investigate the safety and efficacy of TAK-242, as measured by changes in key biomarkers and 28-day survival rates. The trial will be a randomised, double-blind, placebo-controlled study in patients with Grade 1 or 2ACLF.

Hepa Stem: CellaionHepaStem® is in advanced clinical stage of development to treat Acute on Chronic Liver Failure (ACLF). HepaStem®, a cell therapy medicinal product, aims to provide a more accessible and less invasive alternative to liver transplantation. HepaStem® signaling stem cells are administered to the patient intravenously and are transported through the bloodstream to the liver (or other tissues wheretheyare the site of inflammation), where they perform their anti-inflammatory and immunomodulatory function, restoring the health of the organ. Specifically, once injected into the patient, they secrete and exchange cellular compounds (cytokines and other cell derivatives) that neutralize inflammation and prevent tissuedeterioration.

Liver Failure: Therapeutic Assessment

This segment of the report provides insights about the different Liver Failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Liver Failure

There are approx. 12+ key companies which are developing the therapies for Liver Failure. The companies which have their Liver Failure drug candidates in the most advanced stage, i.e. phase II include, Akaza Bioscience.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Liver Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Liver Failure: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Liver Failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liver Failure drugs.

Liver Failure Report Insights

• Liver Failure Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Liver Failure Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Liver Failure drugs?
• How many Liver Failure drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Liver Failure?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Liver Failure therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Liver Failure and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Akaza Bioscience
• Cellaion
• VERSANTIS AG
• Ocera Therapeutics
• Steminent Biotherapeutics
• Go LiverTherapeutics
• Egetis Therapeutics
• Genfit
• Beijing Continent Pharmaceutical
• LyGenesis
• Alnylam Pharmaceuticals
• Novartis

Key Products

• TAK-242
• HepaStem
• VS-01
• OCR-002
• SB-AA01
• Liver disorders stem cell therapy
• Aladote
• GFT1575
• F573
• LYG-LIV-0001

This product will be delivered within 2 business days.